Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma
- PMID: 2499657
- PMCID: PMC2189347
- DOI: 10.1084/jem.169.6.2257
Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma
Abstract
Plasma samples obtained from patients receiving a 24-h continuous infusion of human recombinant (hr)TNF or a combination of two overlapping, 24-h continuous infusions of hrIFN-gamma and hrTNF were analyzed for IL-6 in a sensitive bioassay. A transient appearance of circulating IL-6 was observed with peak levels between 3 and 6 h after the start of the hrTNF infusion. These peak levels correlated quite well with the dose of hrTNF administered (r = 0.86; p less than 0.001). The maximal value observed was 27.5 ng/ml IL-6 in a sample of a patient receiving 545 micrograms/m2 hrTNF. The combination of hrIFN-gamma (200 micrograms/m2) and hrTNF in the infusions resulted in higher IL-6 levels than a comparable dose of hrTNF alone. A maximal value of 23.5 ng/ml IL-6 was observed in a patient receiving 205 micrograms/m2 hrTNF. No IL-6 was found in the plasma of patients during the 12-h infusion with hrIFN-gamma alone, except for two borderline samples.
Similar articles
-
A phase I trial of recombinant human tumor necrosis factor and interferon-gamma: effects of combination cytokine administration in vivo.J Clin Oncol. 1989 Oct;7(10):1545-53. doi: 10.1200/JCO.1989.7.10.1545. J Clin Oncol. 1989. PMID: 2506316
-
Characteristics of fever and acute-phase response induced in rabbits by IL-1 and TNF.Am J Physiol. 1989 Jan;256(1 Pt 2):R35-41. doi: 10.1152/ajpregu.1989.256.1.R35. Am J Physiol. 1989. PMID: 2492162
-
Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans.Cytokine. 1990 Nov;2(6):402-6. doi: 10.1016/1043-4666(90)90048-x. Cytokine. 1990. PMID: 2129506
-
Cytokines modulate interleukin-6 production by human salivary gland cell line.Cell Immunol. 1994 Dec;159(2):211-9. doi: 10.1006/cimm.1994.1308. Cell Immunol. 1994. PMID: 7994755
-
Therapeutic properties of biological response modifiers. A discussion of preclinical and clinical studies.Contrib Gynecol Obstet. 1989;17:49-62. Contrib Gynecol Obstet. 1989. PMID: 2495895 Review. No abstract available.
Cited by
-
Changes in endogenous cytokines, adhesion molecules and platelets during cytokine-induced tumour necrosis.Br J Cancer. 1995 Nov;72(5):1165-72. doi: 10.1038/bjc.1995.481. Br J Cancer. 1995. PMID: 7577463 Free PMC article.
-
Interleukin-6 in clinical medicine.Ann Hematol. 1991 Jun;62(6):203-10. doi: 10.1007/BF01729833. Ann Hematol. 1991. PMID: 1854882 Review.
-
Interleukin-1 and tumour necrosis factor induce hepatic haem oxygenase. Feedback regulation by glucocorticoids.Biochem J. 1991 Nov 1;279 ( Pt 3)(Pt 3):891-4. doi: 10.1042/bj2790891. Biochem J. 1991. PMID: 1835380 Free PMC article.
-
Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis.J Clin Invest. 1994 Aug;94(2):749-60. doi: 10.1172/JCI117394. J Clin Invest. 1994. PMID: 8040330 Free PMC article.
-
Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo.J Clin Invest. 1994 May;93(5):2189-96. doi: 10.1172/JCI117215. J Clin Invest. 1994. PMID: 8182150 Free PMC article.